Abbott Laboratories (ABT) stock experienced a decline of 1.84%, amid UBS maintaining a neutral overall stance on U.S. equities while favoring other healthcare stocks like Eli Lilly, potentially reflecting market volatility and investor sentiment regarding sector performance.

Abbott Laboratories (ABT) stock experienced a decline of 1

Abbott Laboratories (ABT) stock declined by 0.15% amid ongoing legal concerns related to product liability lawsuits involving claims about the risks associated with its infant formulas, particularly in relation to necrotizing enterocolitis (NEC) affecting premature infants.

Abbott Laboratories (ABT) stock declined by 0

Abbott Laboratories (ABT) stock experienced a minor decline of -0.15%, which could be attributed to a competitive investment landscape favoring AI stocks that are perceived to offer greater upside potential with less downside risk.

Abbott Laboratories (ABT) stock experienced a minor decline of -0

Abbott Laboratories' (NYSE:ABT) stock saw a slight increase of 0.08% following a mixed update on its earnings report, which included tightened earnings guidance and lowered sales growth forecasts, indicating cautious optimism in the market despite some reservations from analysts like Jim Cramer. 

The stock's rise can be attributed to the overall positive market conditions at the time of the report.

Abbott Laboratories' (NYSE:ABT) stock saw a slight increase of 0

Abbott Laboratories (NYSE:ABT) stock rose 0.61% after the company reported strong earnings that met analyst expectations and showed a year-over-year revenue increase, despite a reduction in its price targets by Wells Fargo and other firms.

Abbott Laboratories (NYSE:ABT) stock rose 0

Abbott Laboratories (ABT) stock rose by 0.61% after Jim Cramer expressed mixed feelings about the company, noting its potential despite recent declines due to earnings warnings and tariff impacts, suggesting investors might be reacting positively to his long-term optimism.

Abbott Laboratories (ABT) stock rose by 0

Abbott Laboratories (ABT) stock rose by 0.61% due to a combination of analysts' favorable ratings and target price adjustments, with several firms reaffirming or upgrading their buy ratings while the company reported earnings that met expectations and showed revenue growth.

Abbott Laboratories (NYSE: ABT) stock rose by 0.61% despite a slight downgrade in earnings estimates from analysts at Leerink Partners, primarily because the company reported earnings that met expectations and showed strong year-over-year revenue growth.

Abbott Laboratories (NYSE: ABT) stock rose by 0

Abbott Laboratories (ABT) stock rose by 0.61% following a series of mixed but largely positive analyst reports and strong quarterly earnings results that met expectations, along with an increase in revenue from the previous year.

Abbott Laboratories (NYSE: ABT) stock rose 2.62% after Jefferies upgraded it to Buy from Hold, stating that the market's negative reaction to the company's recent earnings report was excessive and that temporary challenges in diagnostics will ease, paving the way for growth driven by new product launches and improving market conditions.

Abbott Laboratories (NYSE: ABT) stock rose 2

Abbott Laboratories (ABT) stock fell nearly 10% despite reporting better-than-expected second-quarter sales and profits due to management's lowered earnings and growth projections for the remainder of the year.

Abbott Laboratories (ABT) stock fell nearly 10% despite reporting better-than-expected second-quarte

Abbott Laboratories (ABT) stock fell by 8.52% due to broader market concerns over speculation regarding the potential ousting of Federal Reserve Chair Jerome Powell, which caused volatility and negatively impacted investor sentiment in the stock market.

Abbott Laboratories (ABT) stock fell by 8

Abbott Laboratories (ABT) stock fell by 8.07% to $121.11 due to concerns about its short-term performance, despite a positive annual growth of 18.71%.

Abbott Laboratories' stock dropped 8.52% after the company reported strong second-quarter revenue growth but failed to meet investor expectations with its forward guidance.

Abbott Laboratories' stock dropped 8

Abbott Laboratories (ABT) stock fell by 8.52% ahead of its earnings report due to market concerns about its financial performance.

Abbott Laboratories (ABT) stock rose by 0.19% recently, though the article primarily discusses legal actions related to other companies such as Vestis, Reckitt, and Tempus, rather than directly addressing the reasons for Abbott's stock increase. 

The stock's increase could be attributed to several factors, including overall market trends, positive investor sentiment, or favorable company performance metrics, although these specifics are not detailed in the article.

Abbott Laboratories (NYSE: ABT) stock recently decreased by -0.41% as traders anticipated the company's upcoming second-quarter earnings announcement, historically marked by a tendency for negative one-day returns following such releases. 

The decline in Abbott Laboratories' stock can be attributed to market anticipation and historical patterns revealing a consistent trend of negative returns after earnings announcements.

Abbott Laboratories (NYSE: ABT) stock recently decreased by -0

Abbott Laboratories (ABT) stock experienced a decline of 1.18%, despite a consensus recommendation of "Moderate Buy" from analysts, likely due to insider selling and general market fluctuations affecting investor sentiment.

Abbott Laboratories (ABT) stock fell by 1.18% due to investor concerns regarding upcoming earnings reports, potential misinterpretation of its quarterly performance, and external factors influencing the healthcare sector, such as competition from GLP-1 weight loss drugs and scrutiny on food products.

Abbott Laboratories (ABT) stock fell by 1

Abbott Laboratories (ABT) stock fell by -1.18% despite analysts raising price targets and maintaining mostly positive ratings, likely due to broader market reactions or profit-taking after recent price increases.

Abbott Laboratories (ABT) stock fell by -1

Abbott Laboratories (ABT) stock rose 0.29% likely due to positive analyst sentiment and expectations for strong upcoming earnings, with projections of $1.25 per share and a revenue of $11.01 billion for Q2 2025, combined with recent upgrades to its price targets by various research firms.

Abbott Laboratories (ABT) stock rose 0

Abbott Laboratories (ABT) stock experienced a slight decline of -0.1% due to concerns over its high valuation relative to the broader market and declining demand for COVID-19 testing, which has impacted its recent revenue growth amidst an uncertain macroeconomic environment.

Abbott Laboratories (ABT) stock experienced a slight decline of -0

Abbott Laboratories (ABT) stock declined by 0.1% despite analysts maintaining an 'Outperform' rating due to ongoing concerns in the market, such as potential volatility and external economic factors influencing investor sentiment.

Abbott Laboratories (ABT) stock saw a slight decline of 0.1% despite an 'Outperform' rating from analysts, as investors may be focusing on more promising AI stocks with higher upside potential, overshadowing the recent positive developments regarding the transcatheter edge-to-edge repair for the tricuspid valve.

Abbott Laboratories (ABT) stock saw a slight decline of 0

Abbott Laboratories (ABT) stock declined by 0.25% amid ongoing class action lawsuits alleging that the company, along with Reckitt Benckiser, failed to adequately inform consumers about the risks associated with their cow milk-based formulas for premature infants, which may contribute to legal claims and affect sales.

Abbott Laboratories (ABT) stock rose by 0.18% due to a general positive market sentiment despite ongoing legal challenges related to claims that their cow milk-based formulas may increase the risk of necrotizing enterocolitis in premature infants, which reflects issues affecting their competitors as well.

Abbott Laboratories (ABT) stock rose 3.62% likely due to positive market sentiment following class action announcements against its competitor, Reckitt Benckiser, regarding legal claims associated with the safety of infant formulas, which may have redirected investor focus and confidence towards Abbott's standing in the market.

Abbott Laboratories (ABT) stock rose 3

Abbott Laboratories' stock (ABT) rose by 0.1% following an upward adjustment in earnings per share estimates by Leerink Partners, which forecasts a EPS of $5.15 for FY2025, slightly higher than the consensus estimate of $5.14, signaling positive investor sentiment amidst strong quarterly earnings performance.

Abbott Laboratories' stock (ABT) rose by 0

Abbott Laboratories (ABT) stock fell by 1.29% due to ongoing class action lawsuits linked to claims that the company failed to adequately warn about the increased risk of necrotizing enterocolitis in premature infants consuming its infant formulas, which has negatively impacted investor confidence.

Abbott Laboratories (ABT) stock experienced a decline of 1.29% despite a promising collaboration with Tandem Diabetes Care to develop integrated diabetes management solutions, potentially due to investor sentiment shifting towards AI stocks perceived to have greater upside potential.

Abbott Laboratories (ABT) stock fell by 1.29% following the initiation of coverage by Leerink Partners, which assigned a market perform rating and a $143 price target, amidst mixed analyst reports indicating an overall moderate buy sentiment but reflecting cautious optimism and potential profit-taking by investors.

Abbott Laboratories (ABT) stock fell by 1.19% despite receiving a "Moderate Buy" rating from analyst firms, possibly influenced by a recent insider selling of shares and a slight miss on quarterly revenue estimates compared to expectations.

Abbott Laboratories (ABT) stock saw a slight decline of -0.13% possibly due to broader market fluctuations or investor reactions to regulatory developments affecting company valuations and relevant tax frameworks.

Abbott Laboratories (ABT) stock saw a slight decline of -0

Abbott Laboratories (ABT) stock decreased by 0.69%, closing at $131.31, likely due to broader market movements affecting pharmaceutical stocks and potential investor concerns regarding regulatory hurdles and competitive pressures in the healthcare sector.

Abbott Laboratories (ABT) stock decreased by 0

Abbott Laboratories (ABT) stock closed down by 0.15%, potentially due to ongoing litigation related to its infant formula business, which continues to cast a shadow over the company's recovery, despite its recent positive performance and growth prospects.

Abbott Laboratories (ABT) stock closed down by 0

Abbott Laboratories' stock (NYSE: ABT) fell by 1.16% amidst an average rating of "Moderate Buy" from research firms, possibly due to mixed earnings results that slightly missed revenue expectations despite exceeding EPS forecasts, as well as insider selling activity that may have raised concerns among investors.

Abbott Laboratories' stock (NYSE: ABT) fell by 1

Abbott Laboratories (ABT) stock declined by 1.59% due to weaker analyst sentiment compared to its competitor CorMedix, which has a stronger consensus rating and higher potential upside, suggesting an overall market perception that favors CorMedix over Abbott.

Abbott Laboratories (ABT) stock declined by 1

Abbott Laboratories' stock (ABT) declined by 1.59% following their investment in Senseonics Holdings, which included purchasing shares as part of Senseonics' public offering, potentially indicating investor concerns about the implications of this investment on Abbott's financial outlook.

Abbott Laboratories' stock (ABT) declined by 1

Abbott Laboratories (ABT) stock experienced a 0.26% decline amid a volatile market environment, influenced by policy uncertainties, economic deceleration, and a shift in investor preference towards defensive sectors and quality stocks, which favored companies like Abbott that are in the healthcare segment.

Abbott Laboratories (ABT) stock experienced a 0

Abbott Laboratories (ABT) stock rose by 1.09% likely due to its agreement to purchase shares of Senseonics Holdings, Inc. in a private placement, which indicates confidence in the growth potential of Senseonics' glucose monitoring technology.

Abbott Laboratories (ABT) stock rose by 1

Abbott Laboratories' (ABT) stock rose by 3.73% following the announcement of its agreement to purchase up to $25 million worth of shares from Senseonics Holdings, Inc. in a concurrent private placement related to Senseonics' public offering aimed at funding the launch of its glucose monitoring systems.

Abbott Laboratories' (ABT) stock rose by 3

Abbott Laboratories' stock is down by 0.38% due to a broader market assessment where it, despite maintaining a solid financial profile with a low P/E ratio, high earnings growth, and strong dividend yield, is trading lower after previously peaking in early March.

Abbott Laboratories' stock is down by 0

Abbott Laboratories (ABT) stock decreased by 0.17% due to broader economic concerns and uncertainties influenced by recent statements from political figures which may affect market sentiment.

Abbott Laboratories (ABT) stock decreased by 0.17% amidst mixed market performance among pharmaceutical companies, with the decline likely influenced by broader market trends and trading volatility rather than specific company issues.

Abbott Laboratories (ABT) stock rose by 0.53% due to positive market sentiment, rising relative strength indicators, and strong seasonality expectations for the healthcare sector, which suggests it may lead ahead as it positions itself for a favorable trajectory into 2025.

Abbott Laboratories (ABT) stock rose by 0.53% in the current market session, attributed to positive sentiment following a recent increase in its share price amid a yearly growth of 22.07%, despite a slight decline over the past month.

Abbott Laboratories (ABT) stock experienced a decline of -1.43% due to a broader market reaction to economic uncertainties and ongoing regulatory scrutiny impacting the healthcare sector.

Abbott Laboratories (ABT) stock experienced a decline of -1

Abbott Laboratories (ABT) stock fell by 1.43% due to concerns over the economic impact of President Trump's tariff policies, which have affected consumer spending and business confidence across various sectors, including healthcare and pharmaceuticals.

Abbott Laboratories (ABT) stock recently experienced a decline of 0.83%, which may be attributed to broader market trends and the strategic adjustments made by the Eaton Vance Worldwide Health Sciences Fund, including increased stakes in other healthcare stocks.

Abbott Laboratories (ABT) stock recently experienced a decline of 0

Abbott Laboratories (ABT) stock rose 4.9% following a better-than-expected earnings report, where the company reported earnings per share of $1.09, surpassing analysts' estimates of $1.07, which contributed to increased investor confidence.

Abbott Laboratories (ABT) stock rose 4

Abbott Laboratories (ABT) stock rose 2.76% due to positive investor sentiment driven by a rebound in banking stocks and renewed foreign fund inflows, alongside favorable macroeconomic indicators such as decreasing retail inflation.

Abbott Laboratories (ABT) stock rose 2

Abbott Laboratories (ABT) stock rose by 2.76% as investors anticipate strong quarterly earnings and significant revenue, with expectations set at $1.07 per share and $10.40 billion, respectively.

Abbott Laboratories (ABT) stock rose by 2

Abbott Laboratories (ABT) stock rose by 2.76% due to the company beating earnings expectations with an adjusted EPS of $1.09 and experiencing significant growth in its medical device division, particularly a 20% increase in diabetes-related products, amidst a generally declining market affected by U.S.-China trade tensions.

Abbott Laboratories (ABT) stock rose by 2.76% despite an early drop following a report of light first-quarter sales, as the company's profits exceeded expectations. The increase in stock price may be attributed to investor optimism around the stronger-than-anticipated profit figures, despite the sales disappointment.

Abbott Laboratories (ABT) stock fell by 1.36% partly due to its historical trend of declining after earnings announcements, which in most cases have resulted in a drop the day after earnings, influencing traders' expectations ahead of its upcoming earnings release.

Abbott Laboratories (ABT) stock fell by 1.36% ahead of its first-quarter earnings report, where analysts anticipate a rise in earnings per share to $1.07 from $0.98 a year earlier; the decline may be attributed to investor uncertainty or profit-taking before the earnings announcement.

Abbott Laboratories (ABT) stock decreased by 1.36% ahead of its upcoming quarterly earnings report due to overall market fluctuations and potential investor concerns, despite positive analyst ratings and projected revenue growth.

Abbott Laboratories (ABT) stock decreased by 1

Abbott Laboratories (ABT) stock experienced a decline of 1.36% primarily due to negative market reactions surrounding its earnings report and broader weaknesses in its sector, akin to the struggles seen by CSX Corporation in freight performance.

Abbott Laboratories (ABT) stock fell by 1.36% following a disclosure of a significant stock purchase by Representative Byron Donalds, which may have raised concerns among investors about insider trading or market sentiment regarding the stock.

Abbott Laboratories (ABT) stock increased by 0.85% ahead of its upcoming quarterly earnings release, where analysts anticipate strong performance with an expected earnings of $1.07 per share and revenue of $10.38 billion, suggesting positive investor sentiment and confidence in the company's continued growth.

Abbott Laboratories (ABT) stock increased by 0

Abbott Laboratories (ABT) stock rose by 1.91%, attributed to expectations of strong earnings within its franchises amid ongoing legal challenges.

Abbott Laboratories (ABT) stock rose 2.49% last night, likely due to positive sentiment surrounding the broader insurance sector's resilience despite market uncertainties and strategic moves by companies like Allstate that may inspire investor confidence in related industries.

Abbott Laboratories (ABT) stock rose 0.18% as analysts have maintained a positive outlook, with a majority recommending it as a "Moderate Buy" and recent price target upgrades from multiple brokerages indicating confidence in the company's future performance.

Abbott Laboratories (ABT) stock was down by 0.4% due to a competitive landscape in the medical diagnostics sector, particularly with analysts favoring Cardio Diagnostics over BG Medicine, highlighting Cardio's stronger consensus ratings and potential upside, which may affect investor sentiment towards Abbott's related partnerships and performance.

Abbott Laboratories (ABT) stock was down by 0

Abbott Laboratories' stock (ABT) fell by 0.4% recently, likely due to broader market trends or specific performance concerns amidst discussions on dividend growth in S&P 500 stocks.

Abbott Laboratories' stock (ABT) fell by 0

Abbott Laboratories (ABT) stock was down by 0.4% due to a revenue miss in the fourth quarter of 2024, which fell short of analysts' expectations by over $57 million, despite the company showing solid overall growth for the year.

Abbott Laboratories (ABT) stock increased by 0.89% due to positive market sentiment surrounding its collaborations and strong positioning in the cardiovascular diagnostics segment, particularly through its partnership with BG Medicine.

Abbott Laboratories (ABT) saw a decline of -1.05% in its stock price recently despite strong growth in its diabetes care segment, which grew 23% year-over-year, as it faces concerns over market competition and medication shortages that impact its product sales and reputation.

Abbott Laboratories (ABT) saw a decline of -1

Abbott Laboratories (ABT) stock decreased by 1.05% to $127.02 amid influential medical stocks trading, likely influenced by market fluctuations and investor sentiment affecting the healthcare sector as a whole.

Abbott Laboratories (ABT) stock increased by 0.73% as several hedge funds adjusted their stakes in the company, with some increasing their holdings, which may reflect positive sentiment and confidence in Abbott's performance and future potential.

Abbott Laboratories (ABT) stock fell by 1.79% despite a recent price target increase by Bank of America and positive analyst ratings, likely due to executive insider share sales and the company slightly missing revenue estimates in its latest earnings report.

Abbott Laboratories (ABT) stock rose 1.53% following a combination of favorable earnings reports meeting estimates, strong institutional investor interest, and positive analyst upgrades.

Abbott Laboratories (ABT) stock rose 1

Abbott Laboratories (ABT) stock increased by 1.53% after Goldman Sachs raised its price target for the company from $138.00 to $154.00, alongside multiple analysts issuing positive ratings and target price adjustments for the stock.

Abbott Laboratories (ABT) stock increased by 1

Abbott Laboratories' stock (NYSE:ABT) fell by 1.91% after reaching a 52-week high earlier, despite Citigroup raising its price target for the stock, likely influenced by mixed sentiments from analysts, insider share sales, and concerns regarding the company's recent earnings results missing revenue estimates.

Abbott Laboratories' stock (NYSE:ABT) fell by 1

Abbott Laboratories (ABT) stock rose 0.09% following Citigroup's upgrade of its price target from $135.00 to $160.00, along with favorable ratings and price target increases from multiple analysts, indicating strong investor confidence in the company's growth outlook.

Abbott Laboratories (ABT) stock was down 1.88% following unusual options trading activity and mixed earnings results that slightly missed revenue expectations, despite the company meeting earnings per share estimates.

ABT

Latest News & Analysis